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ABSTRACT
Myofascial pain syndrome (MPS) is defined as
pain that originates from myofascial trigger
points in skeletal muscle. It is prevalent in
regional musculoskeletal pain syndromes,
either alone or in combination with other pain
generators. The appropriate evaluation and
management of myofascial pain is an important
part of musculoskeletal rehabilitation, and
regional axial and limb pain syndromes. This
article reviews the current hypotheses regarding
the treatment modalities for myofascial trigger
points and muscle pain. Through a critical
evidence-based review of the pharmacologic
and nonpharmacologic treatments, the authors
aim to provide clinicians with a more
comprehensive knowledge of the interventions
for myofascial pain.
Keywords: Analgesics; Anticonvulsants;
Muscle relaxants; Myofascial pain;
Nonpharmacological treatment; Pain;
Treatment
INTRODUCTION
The conventional definition of myofascial pain
syndrome (MPS) is characterized by regional pain
originating from hyperirritable spots located
within taut bands of skeletal muscle, known as
myofascial trigger points (MTrPs) [1]. Common
etiologies of myofascial pain and dysfunction
may be from direct or indirect trauma, spine
pathology, exposure to cumulative and repetitive
strain, postural dysfunction, and physical
deconditioning [2, 3]. Treating the underlying
etiology is currently the most widely accepted
strategy for MPS therapy. If the root cause is not
properly treated, MTrPs may reactivate and MPS
may persist [2].
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Interestingly, there is a lack of specific
diagnostic criteria for MPS. Electrodiagnostic
and morphological findings have been
identified; however, they cannot be practically
applied in the clinical setting due to cost and
time constraints. This adds to the difficulty of
definitive treatment, particularly when
considering elusive underlying pathology and
persistent MTrPs.
The aim of this article is to examine the
variety of treatments for MPS. Specifically, the
evidence basis of pharmacological treatment
and noninvasive therapy are reviewed. The
purpose of this review is to provide the
clinician with a comprehensive and up-to-date
understanding of the current treatments for
MPS.
MATERIALS AND METHODS
An extensive literature search was performed to
create a comprehensive narrative in the
treatments for myofascial pain. This was done
by searching PubMed, Ovid, and Google Scholar
for the key terms: \intervention of interest[
and ‘‘myofascial pain’’ or ‘‘muscle pain.’’
Controlled studies were given first priority,
followed by observational studies. Systematic
reviews and Cochrane reviews were included,
and non-English sources were omitted. Given
the considerable clinical overlap among
musculoskeletal (MSK) disorders, e.g.,
fibromyalgia, regional soft-tissue pain,
craniomandibular dysfunction, and tension
headache, methods beneficial to an associated
syndrome may prove useful in treating
myofascial pain. In the absence of controlled
data specifically examining drug efficacy in
myofascial pain, the authors extrapolated from
these associated disorders. Relevant studies with
stronger levels of evidence were compiled and
summarized for each method, and clinical
recommendations were generated. It should be
noted that the diagnostic criteria for MPS might
vary between studies, so the conclusions drawn
on the efficacy of various therapies must be
taken with caution.
PHARMACOLOGIC TREATMENT
OF MYOFASCIAL PAIN
Analgesic Drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs)
are the most commonly used drugs for MPS
as they are readily available and have a relatively
mild side-effect profile. Their use is appealing
because of their analgesic and
anti-inflammatory properties. Despite their
widespread use, there are no randomized,
controlled trials (RCTs) specifically evaluating
oral NSAIDs in the treatment of MPS. Therefore,
there is a lack of strong evidence for the role of
an anti-inflammatory in MPS [4]. Multiple
studies exist that demonstrate strong evidence
in support of NSAIDs in treating acute MSK
disorders, particularly low-back pain (LBP) [5–7].
Although the role of NSAIDs in treating MPS is
unclear, there is clear evidence that the analgesic
properties of NSAIDs relieve pain in acute
MSK disorders [5–7]. With the considerable
overlap between MPS and MSK pain, it would
be reasonable to consider NSAIDs as an
appropriate initial treatment in both disorders.
However, long-term use should be considered
with caution due to the gastrointestinal, renal,
and antiplatelet side effects [6].
A diclofenac patch was evaluated in a RCT for
myofascial pain of the trapezius muscle. There
were statistically significant benefits with the
diclofenac patch for pain (P\0.01), cervical
range of motion (ROM) (P\0.01), and neck
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disability index (P = 0.03) by the end of
treatment. The study demonstrated good patch
tolerability and low overall skin irritation
midway and at the end of the study [8].
Cyclooxygenase-2 (COX-2) inhibitors have
an analogous effect to traditional NSAIDs with a
relatively more-tolerable side-effect profile.
Similar to NSAIDs, there are few supporting
RCTs and evidence for their efficacy in MPS.
Studies have shown that COX-2-selective
inhibitors are an effective and well-tolerated
agent for acute LBP [9, 10]. Many studies have
examined their effect on joint pain and chronic
pain, which is outside the scope of this review.
These agents should be considered in patients
who are more prone to gastrointestinal side
effects and do not have a history of thrombotic
cardiovascular disease.
Tramadol is a centrally acting mu-receptor
agonist, an inhibitor of dorsal horn presynaptic
norepinephrine/serotonin reuptake, and
increases central serotonin release. Studies have
shown that tramadol is an effective and
well-tolerated agent for use in LBP, some chronic
pain syndromes, and osteoarthritis [11, 12]. With
regard to myofascial pain, there are no studies
investigating the efficacy of this agent;however, it
is used often for its multimodal analgesic effects
and low abuse potential [11, 13–15].
Tropisetron is a 5-HT3 receptor antagonist and
alpha-7-nicotinic receptor agonist recently used
as an analgesic for fibromyalgia and myofascial
pain with a limited commercial availability. In a
RCT, local injections of tropisetron at trigger
points provided a statistically significant
improvement in pain (P = 0.006) [16]. Its effects
began rapidly and lasted longer than those of
local anesthetics. Although this may appear a
promising treatment for MPS, most of the
available studies were written by the same
group of authors, and thus, this requires further
investigation.
Opioids are not normally indicated in the
treatment for MPS. Although some limited
studies demonstrate that weak opioids are
moderately effective in the treatment of
myofascial pain [17], most studies do not
support the use of opioids in MPS.
Furthermore, it is suggested that the use of
opioids for the management of acute pain may
actually be counterproductive to recovery [18].
The lidocaine patch is a transdermal local
anesthetic preparation that alters the ability of
nerves to conduct pain impulses [19]. A number
of RCT studies, case reports, and observational
studies examining the efficacy of lidocaine
patches on MPS have been conducted. These
studies were congruent in showing that
lidocaine patches had a statistically significant
increased pain thresholds (P\0.001), and
increase in general activity (P\0.05) [20–22].
Topical lidocaine has shown promise as a
therapy for MPS and is especially appealing as
it is not an oral systemic drug.
Muscle Relaxants
Tizanidine is a centrally acting
alpha-2-adrenergic agonist, which decreases
muscle spasticity. An open-label, dose-titration
study of tizanidine for MPS supported a
significant decrease in pain intensity and
disability from baseline (P\0.01), and with
improved sleep study periods [23]. Its efficacy in
treating acute LBP has also been documented.
Studies have suggested that tizanidine should be
considered as a first-line agent for the treatment of
MPS [23].
Benzodiazepines depress the presynaptic
release of serotonin and excite gamma-
aminobutyric acid (GABA), which causes rapid
inhibitory neurotransmission. In an open
clinical trial, clonazepam was postulated to
have an antinociceptive effect associated with
Pain Ther (2013) 2:21–36 23
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MPS as it showed a statistically significant
decrease in pain (P\0.001) [24]. There are no
RCTs evaluating the efficacy of clonazepam for
MPS. Although there are limited data in the
setting of MPS, a review of 30 RCTs was
performed in 1997 to evaluate muscle
relaxants on acute and chronic nonspecific
LBP. The review showed that the use of muscle
relaxant treatments is effective, but the
associated adverse effects require that they be
used with caution [6].
Cyclobenzaprine is another muscle relaxant
that was recently studied in a Cochrane
literature review. This review demonstrated
a statistically significant decrease in mean
pain intensity from baseline compared
to clonazepam (P = 0.002) [1]. Another
double-blind RCT compared cyclobenzaprine ?
ibuprofen versus placebo ? ibuprofen in
patients with acute myofascial pain [25]. There
was no statistically significant difference in pain
scores (P = 0.962) [25], but treated patients
reported greater central nervous system side
effects [25]. Cyclobenzaprine is efficacious as a
muscle relaxant; however, there are no data to
support treatment for MPS.
Thiocolchicoside (TCC) is a competitive
GABAA antagonist and glycine agonist that
also functions as an anti-inflammatory and
analgesic [26], as well as a muscle relaxant
[27]. A RCT in the setting of cervical myofascial
pain demonstrated a statistically significant
improvement in pain severity (P\0.001) and
ROM in those treated with topical TCC [28]. A
double-blind RCT evaluating acute LBP
associated with muscle spasm, supported the
effectiveness of TCC and tizanidine over
placebo in improving pain at rest, although
tizanidine did cause somnolence [29]. There is a
potential for TCC as a treatment in myofascial
pain; however, there is limited evidence at this
time.
Anticonvulsants
Gabapentin and pregabalin have analgesic,
anxiolytic-like, and anticonvulsant activity,
which reduces the release of several
neurochemicals, including glutamate,
noradrenaline, and substance P [30]. MPS may be
mediated at the spinal level; therefore,
anticonvulsants might be considered in its
treatment [31]. To date, there are no RCTs of
anticonvulsants in the treatment of MPS.
A Cochrane literature review found that very few
trials examined anticonvulsant effectiveness on
acute pain; most examined their use in chronic
pain [32]. A multicenter, double-blind RCT
compared the effects of placebo with pregabalin
on fibromyalgia. This demonstrated a
significantly reduced average severity of pain in
the pregabalin group and significantly more
patients in this group had[50% improvement in
pain (P = 0.003) [30]. Although anticonvulsants
may have a therapeutic role in fibromyalgia, there
is no evidence that they are effective for MPS and
should be withheld until other interventions have
been attempted [32].
Antidepressants
Tricyclic antidepressants (TCAs) are a class of
medications that have been indicated for
chronic pain, fibromyalgia, and neuropathic
pain [33, 34]. Their pain mitigating effects are
not clear, but it is postulated that TCAs work on
central serotonergic and noradrenergic signals,
which affect central pain pathways [35].
Although their use is widespread, there are
limited studies specifically for the treatment of
MPS. A crossover study investigated the
therapeutic effect of amitriptyline in treating
chronic tension headaches and understanding
its mechanism of action [36]. Compared
to placebo, amitriptyline demonstrated a
24 Pain Ther (2013) 2:21–36
123
statistically significant reduction in tenderness
(P = 0.01) and a highly significant reduction in
headache intensity [36]. The study attributed
this reduction to decreased neurotransmission
of painful stimuli from the muscles rather than
a general decrease in pain sensitivity [36].
Another study investigated amitriptyline use
in the treatment of chronic temporomandibular
disorder pain and showed a statistically
significant reduction in all pain scores after
6 weeks of treatment (global treatment
effectiveness, P = 0.007) [37]. Currently, there
is no indication for the use of these medications
in the treatment of MPS; however, the growing
body of evidence for their efficacy in chronic
pain syndromes suggests an increased role in
MPS when conventional treatments fail.
Duloxetine, a serotonin-norepinephrine
reuptake inhibitor (SNRI), was recently found
to be an evolving and possibly efficacious
treatment for painful MSK conditions. As more
research continues to be produced, this may
prove to be especially useful in patients that also
suffer from neuropathic pain or other mood
disorders. A clinician must be vigilant of the
numerous side effects of SNRIs (i.e., nausea,
fatigue, diarrhea, hyperhidrosis, dizziness,
constipation, and dry mouth) as well as its
interaction with other medications [38].
Sumatriptan is a peripheral 5-HT receptor
agonist commonly used for migraines. Data
suggest that serotonin plays a role in the
pathophysiology of myofascial pain [39].
A RCT examined its efficacy in reducing pain in
patients with temporal muscle pain [40] and
yielded a statistically significant reduction
in pain intensity and increased pain relief
(P\1 9 10-10) [40]. However, when compared
to the placebo there was no significant difference
(P\0.57) [40]. This study demonstrated an
effective use of sumatriptan; however, more
studies are required before endorsing this is a
mainstream treatment for MPS.
Other Treatments
Botulinum type A toxin (BoNT-A) is a potent
neurotoxin that prevents muscle contraction.
Its use in the treatment of muscle pain has been
a topic of investigation recently and shows
promise. It may have analgesic properties
through decreased production of substance P
and glutamate [41].
A recent, multicenter, prospective,
randomized, double-blind study was
conducted to evaluate the efficacy and
tolerability of injections of BoNT-A at fixed
locations in patients with moderate-to-severe
myofascial pain of the upper back [42]. The
study demonstrated a statistically significant
difference in pain intensity, duration, and
reduction of trigger points of the BoNT-A
group (P = 0.001); however, these effects were
seen after 4 weeks. An earlier study by the same
group demonstrated similar results [43].
A Cochrane literature review that only
included RCTs also evaluated BoNT-A in the
setting of MPS. One of the four studies produced
a statistically significant decrease in pain
intensity scores and duration (P\0.00001)
[44]. Another literature review found one of
five studies had a statistically significant benefit
for treatment with BoNT-A (P\0.01) [45].
Freund and Schwartz [46] found a statistically
significant improvement in pain scores in
patients treated with BoNT-A (P\0.01). Lastly,
when compared to saline injection, one study
showed improvements in a visual analog scale;
however, they were not statistically significant.
Contrary to this evidence, two studies
compared BoNT-A to placebo and showed no
significant improvement in pain [47, 48].
Pain Ther (2013) 2:21–36 25
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Finally, two studies compared BoNT-A to
bupivacaine and BoNT-A to lidocaine trigger
point injections, respectively [49, 50]. Each
treatment showed improvement but there was
no significant difference between groups [49,
50].
The literature suggests that BoNT-A injection
is a promising therapy to alleviate MPS,
especially when it persists despite conservative
treatment. Another appeal is that the side
effects of muscle weakness and paralysis are
transient, mostly local, and reversible [51].
Ketamine is a dissociative anesthetic, analgesic,
and sedative that works as a noncompetitive
N-methyl-D-aspartic acid (NMDA) receptor
antagonist. A RCT studied the use of
intramuscular ketamine in the treatment of
chronic myofascial pain in temporomandibular
disorder. The study showed there was no
statistically significant benefit to treatment with
ketamine [52].
L-tryptophan and memantine are drugs that
have been studied for the treatment of pain;
however, these are older studies and there has
been no recent research indicating their use in
the treatment of myofascial pain [53].
A summary of pharmacologic treatments for
myofascial pain can be found in Table 1 [1, 16,
17, 20–25, 28, 36, 37, 40, 42–50, 52, 53].
NONPHARMACOLOGIC
TREATMENT OF MYOFASCIAL PAIN
Injections into MTrPs are a common and
effective treatment, presumably due to
mechanical disruption by the needle and
termination of the dysfunctional activity of
involved motor endplates [39]. MTrP
injections may employ dry needling, short- or
long-acting anesthetics, or steroids.
Dry needling has been traditionally used as
one of the fastest and most-effective ways to
inactivate MTrPs and help alleviate the
accompanied pain. The needle is placed into
MTrPs using an in-and-out technique in
multiple directions, in order to inactivate the
MTrP. There are many studies investigating the
effectiveness of dry needling; however, RCTs are
difficult to design given the invasive nature of
the procedure. In one study where patients
underwent dry needling with and without
lidocaine, it was concluded that both were
effective in reducing MPS when eliciting local
twitch responses during the procedure [54]. In
another study with patients who were to
undergo knee surgery, patients underwent dry
needling or not while under general anesthesia
and were evaluated postoperatively. This novel
approach demonstrated significant a superiority
of dry needling versus placebo in postsurgery
analgesic demand (P = 0.02) and visual analog
scores 1 month after surgery (P\0.04) [55].
Several other studies by various authors have
shown that dry needling is an effective
treatment and equal in efficacy to trigger
point injections, and should be used as the
mainstay of acute treatment, despite complaints
of postinjection soreness [39, 56].
Trigger point injections are similar to dry
needling; however, they inject various solutions,
typically a local anesthetic. Studies suggest similar
efficacy to dry needling but with less discomfort
[50]. A recent systematic review article on
needling therapies for MTrPs found that, based
on current medical evidence, the ‘‘nature of the
injected substance makes no difference to the
outcome and that wet needling is not
therapeutically superior to dry needling’’ [57].
Steroid injections into MTrPs are
controversial and without clear rationale
26 Pain Ther (2013) 2:21–36
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because little evidence exists to support an
underlying inflammatory pathophysiology [39].
Manual therapy is a commonly used
treatment for MPS as it has been considered as
one of the most effective techniques for the
inactivation of MTrPs [2, 58]. There are various
sources in the literature, which have specifically
described effective modalities, including
deep-pressure massage [59], stretch therapy
with spray (where a taut band is stretched
immediately after cold spray), superficial heat,
and myofascial release [60]. Although there are
many techniques that have been described in
treating MPS with effective results, there have
been no controlled studies proving significant
long-term effectiveness.
Ultrasound is a technique that has been
proposed to treat myofascial pain by converting
electrical energy to sound waves in order to
provide heat energy to muscles [61]. Multiple
studies of ultrasound on MPS have been
conducted; however, most demonstrate mixed
results. A meta-analysis by Gam and Johannsen
[62] reviewed 293 papers published since 1950
to assess the evidence for ultrasound in the
treatment of MSK disorders. This found no
documentation of effect; furthermore, the
literature was generally of poor quality.
More recent RCTs have also been conducted. In
one study on the treatment of latent MPS of the
trapezius, ultrasound decreased the basal level of
electricalactivityandreduced the sensitivityof the
trigger points [63]. Another RCT evaluating MTrP
of the infraspinatus demonstrated a statistically
significant increase in pain pressure threshold
(P\0.002) [64]. Another RCT compared
ultrasound to diclofenac phonophoresis and
placebo, which demonstrated a statically
significant improvement in pain, ROM, number
of trigger points, and neck pain disability index
amongst the two former modalities (P\0.05) [65].
There was no significant difference between theT
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two treatment groups in those outcome
measurements [65]. A similar study undertaken
in 2012 examined the use of pressure release,
hydrocortisone phonophoresis, ultrasound
therapy, and placebo for the treatment of upper
trapezius MTrPs. All three treatment groups
demonstrated a statistically significant decrease
in pain, and increase in pain threshold and
ROM (P\0.001) [66]. Pressure release and
phonophoresis had superior therapeutic effects
compared to ultrasound [66]. Likewise, another
study concluded no statistically significant
reduction in pain or analgesic usage between
ultrasound ? massage, sham ultrasound ?
massage, and exercise versus control [61].
The use of high-powered ultrasound has also
been explored. A RCT study resulted in a
statistically significant improvement in neck
pain scores when compared to conventional
ultrasound (P\0.05) [67].
Transcutaneous electric nerve stimulation
(TENS) is a treatment modality that utilizes an
electrical current to stimulate nerve fibers in order
to provide pain relief. TENS has been studied since
1970s and has recently been evaluated for the
treatment of MPS [68]. One study in muscular
face pain compared the use of TENS to
biofeedback-enhanced relaxation and dental
physiotherapy. It was shown that all three groups
had equivalent results [68]. In a double-blind RCT,
fourmodesofTENSwerecompared tocontrols and
demonstrated that there was a significant
reduction in pain with three of four modes:
100 Hz, 250 ms; 100 Hz, 50 ms; pain suppressor
TENS (P\0.001) [69]. Another RCT resulted in a
statistically significant reduction in pain and
increase in pain threshold versus control and
electrical muscle stimulation (P\0.01) [70].
TENS was further studied in another RCT that
looked at TENS versus ultrasound versus
TENS ? ultrasound versus control. Ultrasound
alone showed no significant benefit, whereas
TENS did show a reduction in pain immediately
after therapy [71]. Another RCT looked at TENS
versus frequency-modulated neural stimulation
(FREMS) for the treatment of MPS [72]. It was
shown that both TENS and FREMS had significant
improvement in neck pain in the short term
(P\0.001) [72]. Finally, a 2009 RCT investigated
TENS versus laser therapy versus lidocaine
injection versus BoNT-A injection in patients
with myofascial pain [73]. This study is one of the
few to compare TENS to trigger point injections.
It demonstrated no statistically significant
benefit over injections [73]. Overall, TENS has
been shown to have benefit among the
noninvasive therapeutic modalities; however,
there is currently no evidence that supports its
use over trigger point injections or medication. At
this point, TENS can be used as an adjuvant
therapy to help alleviate MPS but should not be
considered a monotherapy.
Electrical twitch obtaining intramuscular
stimulation (ETOIMS) is another method of
using an electrical current through a
monopolar electromyography needle to engage
deep motor endplates. Chu et al. [74] conducted
separate studies on the use of ETOIMS specific to
myofascial pain. A pilot study demonstrated a
significant reduction in pain levels immediately
after treatment in the ETOIMS group and these
effects were sustained for 2 weeks posttreatment
(P\0.05) [74]. Another study in the setting of
chronic refractory MPS resulted in significant
improvement in immediate pain levels and
ROM with no major side effects (P\0.01) [75].
Furthermore, a significant negative correlation
between number of treatments and pain level
was noted (P = 0.00) [75]. ETOIMS has shown
some potential as a treatment method; however,
there is still a lack of RCTs; therefore, its use in
MPS cannot be endorsed at this time.
Magnetic stimulation (MS) is a newer
treatment that is being investigated for MSK
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pain and MPS. Only a limited number of studies
exist and the exact therapeutic mechanism of
action remains uncertain [76]. In evaluating
MS, one RCT concluded that it affords
significant improvements in pain level
(P\0.01) and ROM (P\0.035), and lasted for
1 month versus placebo [77]. Another RCT
study compared MS to TENS and placebo. The
results showed that MS had a statistically
significant improvement in pain and ROM at 1
and 3 months after treatment, longer than the
beneficial effects obtained after TENS (P\0.05)
[78]. MS has shown potential as a possible
treatment method; however, more evidence is
required before advising it as an efficacious
treatment strategy.
Laser therapy has been used in the treatment
of MSK pain including MPS; however, its exact
mechanism of therapeutic action remains
elusive. A 2004 RCT investigated laser versus
placebo in the treatment of MPS and its effects on
serotonin, a mediator of pain. Laser treatment
demonstrated a statistically significant reduction
in pain and increases in urinary excretion of
serotonin degradation (P\0.05) [79]. Multiple
RCTs have determined a statistically significant
improvement in pain with laser therapy
(P\0.01; P\0.002) [80, 81]. Yet another RCT
study examined stretching with laser therapy and
concluded that the laser treatment group had
significantly decreased pain levels at the 3-week
follow-up (P\0.05) [82]. When comparing laser
therapy with dry needling and placebo, a RCT
showed that laser therapy significantly decreased
overall pain and increased the pain threshold
compared to the latter groups (P\0.05) [83].
However, these benefits were no longer present at
6 months [83].
There is significant contradictory evidence for
the benefit of laser therapy. A double-blind RCT
investigated laser therapy versus placebo in the
treatment of cervical myofascial pain. The
authors concluded that there was no statistical
difference between the two groups [84]. Another
study analyzed laser therapy and found no
significant benefit to its use [85]. Adding to this
result, a 2005 study demonstrated that laser
therapy did not have a significant benefit over
placebo [86]. A 1992 study also concluded no
beneficial effect for laser therapy in patients with
myofascial pain [87]. Although laser therapy has
shown some therapeutic promise, as a whole the
body of evidence is mixed regarding the efficacy
of this treatment strategy. At this point, the
authors cannot endorse laser therapy as an
appropriate treatment.
A summary of nonpharmacologic treatments
for myofascial pain can be found in Table 2 [50,
54–57, 59–67, 69–75, 77–87].
CONCLUSION
This review of treatment in MPS finds that
most interventions demonstrate a limited body
of evidence for their use. This dearth of
high-quality evidence is likely due to the
heterogeneity of MPS combined with study
design and methodologies. The treatment for
MPS should focus primarily on identifying and
correcting the underlying cause of the symptoms.
The complex pathology of MPS with its
underlying central and peripheral neural
mechanisms may contribute to the difficulty in
treating MPS, particularly in the chronic setting.
With regards to the pharmacologic
treatments reviewed, tizanidine, benzodiazepines,
and tropisetron appear to demonstrate some
limited evidence for their use. Topical
diclofenac and lidocaine patches may also
have limited efficacy. TCC is a promising
agent. There is evidence that NSAIDs and
COX-2 inhibitors alleviate pain; however,
more controlled trials are required to fully
determine their role in MPS.
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Of the modalities reviewed, dry needling and
trigger point injections are the mainstay of
interventional treatment. Multiple studies
support their use, but sustainability is likely
based on using these therapies judiciously and
in conjunction with manual therapies, such as
myofascial release. Newer therapies, such as
ultrasound and laser therapy, show promise.
Further research is needed to better establish
algorithmic and evidence-based treatment of
MPS.
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